CagriSema vs Zepbound: 2026 Head-to-Head Trial Results Explained

I. Why CagriSema vs Zepbound Matters Right Now

On February 23, 2026, a single clinical trial result wiped roughly $30 billion from Novo Nordisk's market cap in a matter of hours. The company's stock dropped about 15% before most people had finished their morning coffee. What happened?

Novo Nordisk's next-generation obesity drug, CagriSema, went head-to-head against Eli Lilly's Zepbound (tirzepatide) in the REDEFINE 4 trial -- the first direct comparison between these two drugs. CagriSema lost. Not by a dramatic margin, but it lost. And the market reacted as if Novo Nordisk had announced it was getting out of the obesity business entirely.

Here's the thing: CagriSema still produced 23% body weight loss over 84 weeks. That's an extraordinary result by any historical standard. But in the current obesity drug arms race, "extraordinary" isn't enough if your competitor hits 25.5%.

This article breaks down the CagriSema vs Zepbound comparison in full. We'll walk through how each drug works, what the REDEFINE 4 trial actually showed, how the side effect profiles compare, and what all of this means if you're a patient trying to make sense of your options. We'll also place these results in the broader context of a pipeline that includes triple agonists, oral formulations, and next-generation drugs that could make both CagriSema and Zepbound look modest by comparison.

The peptide therapeutics market is projected to reach $49.68 billion in 2026. The "obesity drug wars" aren't slowing down. If anything, the REDEFINE 4 results just made the competition more intense.

For a deeper look at CagriSema's full research profile, see our CagriSema combination therapy profile. And if you're new to the question of whether peptide-based drugs actually work for weight management, start with our FAQ: do peptides work for weight loss?

II. What Is CagriSema? The Dual-Mechanism Approach

The Components

CagriSema is a fixed-dose combination of two drugs in a single weekly injection:

Semaglutide 2.4 mg -- a GLP-1 receptor agonist. This is the same active ingredient in Wegovy (for weight management) and Ozempic (for type 2 diabetes). If you've heard of either of those drugs, you already know half of CagriSema. For more on how they differ, see Ozempic vs Wegovy: same drug, different use.
Cagrilintide 2.4 mg -- a long-acting amylin analog. This is the newer, less familiar half. Amylin is a hormone your pancreas releases alongside insulin after meals. It tells your brain you're full, slows the rate at which food leaves your stomach, and reduces post-meal spikes in glucagon (a hormone that raises blood sugar). Natural amylin breaks down in minutes. Cagrilintide is engineered to last long enough for once-weekly dosing.

The name "CagriSema" is just a mashup of its two components: Cagrilintide + Semaglutide.

How the Dual Mechanism Works

The bet behind CagriSema is straightforward: two appetite pathways are better than one.

The GLP-1 pathway (semaglutide's contribution) works primarily through the hypothalamus -- the brain region that regulates hunger. GLP-1 slows gastric emptying, reduces appetite signaling, and improves insulin sensitivity. It's the proven workhorse behind drugs like Wegovy and Ozempic.

The amylin pathway (cagrilintide's contribution) operates through a different set of neural circuits. Amylin acts on the area postrema and the hindbrain to produce satiety. It also slows gastric emptying, but through distinct mechanisms from GLP-1. And it suppresses post-meal glucagon secretion, which helps stabilize blood sugar.

The theory: since GLP-1 and amylin reduce appetite through independent pathways, combining them should produce additive weight loss that neither drug could achieve alone. The early trial data backed this up. CagriSema produced more cagrisema weight loss than semaglutide by itself in every trial where they were compared.

Whether that additive benefit is enough to compete with tirzepatide's dual-agonist approach -- that's exactly what the REDEFINE 4 trial was designed to answer.

The REDEFINE Clinical Trial Program

CagriSema has been tested across a series of Phase 3 trials, each designed to answer a different question:

REDEFINE 1 (published in the New England Journal of Medicine, June 2025): CagriSema vs placebo in adults with obesity but without type 2 diabetes. Over 68 weeks, CagriSema produced 20.4% mean body weight loss compared to 4.5% with placebo. A strong showing against placebo.

REDEFINE 2 (published in the NEJM, 2025): CagriSema vs semaglutide + placebo in adults with obesity and type 2 diabetes. CagriSema delivered 15.7% weight loss at 68 weeks vs 8.2% for semaglutide alone -- confirming the cagrilintide adds meaningfully on top of semaglutide.

REDEFINE 4 (reported February 2026): The big one. CagriSema vs Zepbound (tirzepatide), head-to-head, over 84 weeks. We'll break this down in detail in Section IV.

REDEFINE 11 (upcoming): A higher-dose CagriSema trial, expected to begin in H2 2026 with results anticipated in H1 2027. This could change the competitive picture if higher doses close the gap with tirzepatide.

III. What Is Zepbound (Tirzepatide)? The Current Market Leader

The Mechanism

Zepbound is the brand name for tirzepatide when prescribed for weight management. (The same molecule is sold as Mounjaro for type 2 diabetes.) It's made by Eli Lilly.

Tirzepatide is a dual GIP and GLP-1 receptor agonist -- a single molecule that activates two incretin pathways simultaneously. While CagriSema combines two separate drugs, tirzepatide is one molecule doing two jobs.

GIP (glucose-dependent insulinotropic polypeptide) is another gut hormone released after eating. For years, researchers debated whether GIP activation would help or hinder weight loss. Tirzepatide settled the argument. Adding GIP agonism to GLP-1 activity boosts insulin secretion, improves fat metabolism, and -- based on the trial data -- produces more weight loss than GLP-1 drugs alone.

For a detailed comparison of the underlying mechanisms, see our semaglutide vs tirzepatide comparison.

The Clinical Track Record

Tirzepatide's clinical data is, frankly, hard to argue with.

The SURMOUNT trial program tested tirzepatide at doses up to 15 mg weekly in thousands of participants. SURMOUNT-1 showed about 21% mean body weight loss at 72 weeks. Longer-duration follow-up from SURMOUNT-4 pushed that number toward 25%.

Based on this data, Zepbound received FDA approval for chronic weight management in adults in June 2024. Mounjaro (same drug, different label) had already been approved for type 2 diabetes.

As of early 2026, tirzepatide is the most effective FDA-approved drug for weight loss. That's the bar CagriSema was trying to clear.

IV. The REDEFINE 4 Trial: Head-to-Head Results

This is the section most people are here for. The REDEFINE 4 trial is the first time CagriSema and Zepbound were tested against each other in the same study, with the same patients, under the same conditions. Here's what the cagrisema trial results 2026 showed.

Trial Design

The study details (NCT06131437):

Type: Phase III, open-label, randomized
Duration: 84 weeks
Participants: 809 adults with obesity (BMI meeting clinical criteria) plus at least one weight-related comorbidity
Mean baseline body weight: 114.2 kg (about 252 pounds)
Treatment arms: CagriSema 2.4/2.4 mg vs tirzepatide 15 mg, both given as weekly subcutaneous injections
Primary endpoint: Non-inferiority of CagriSema compared to tirzepatide for percentage body weight loss

That primary endpoint is worth pausing on. Novo Nordisk wasn't trying to prove CagriSema was better than Zepbound. They were trying to prove it was not meaningfully worse. In clinical trial language, that's called non-inferiority. If CagriSema's weight loss fell within a predefined margin of tirzepatide's, the trial would be considered a success.

It's also worth noting this was an open-label trial -- both patients and researchers knew which drug each participant was receiving. This is relevant for interpreting side effect reports, which we'll address in Section V.

Key Results

On-treatment analysis (trial product estimand): Among patients who stayed on their assigned drug throughout the trial, CagriSema produced 23.0% mean body weight loss. Zepbound produced 25.5%.

Intent-to-treat analysis (treatment regimen estimand): Looking at all randomized patients regardless of whether they completed treatment, CagriSema delivered 20.2% mean body weight loss. Zepbound delivered 23.6%.

The bottom line: CagriSema did not meet the primary endpoint of non-inferiority vs tirzepatide. The 2.5 to 3.4 percentage point gap between the two drugs was larger than the predefined non-inferiority margin.

An interesting detail came from Novo Nordisk's Chief Scientific Officer, Martin Holst Lange, who noted that tirzepatide performed "unusually well" in this particular trial -- outpacing its own results from the SURMOUNT program. Whether that's a statistical quirk, a population effect, or simply what happens when you run a trial with 809 patients is debatable. But it does add context.

Let's also be clear about what 23% weight loss means in absolute terms. For a person weighing 114 kg (the trial average), CagriSema produced roughly 26 kg (about 57 pounds) of weight loss. Zepbound produced roughly 29 kg (about 64 pounds). The clinical difference between losing 57 and 64 pounds is real, but both numbers represent transformative outcomes for patients with obesity and related health conditions.

Head-to-Head Comparison Table

Parameter	CagriSema (2.4/2.4 mg)	Zepbound (tirzepatide 15 mg)
Mechanism	GLP-1 + amylin analog	GLP-1 + GIP dual agonist
Manufacturer	Novo Nordisk	Eli Lilly
Weight loss (on-treatment, 84 wk)	23.0%	25.5%
Weight loss (intent-to-treat, 84 wk)	20.2%	23.6%
Non-inferiority met?	No	N/A (comparator)
Trial name	REDEFINE 4	REDEFINE 4
Trial population	809 adults with obesity + comorbidities	Same trial
Baseline body weight (mean)	114.2 kg	114.2 kg
Duration	84 weeks	84 weeks
Delivery	Weekly subcutaneous injection	Weekly subcutaneous injection
FDA status	Filed Dec 2025 (decision expected late 2026)	Approved (obesity: Jun 2024)
Key prior trials	REDEFINE 1 (20.4% vs placebo)	SURMOUNT-1 (~21% at 72 wk)

V. Safety and Side Effects: CagriSema vs Zepbound

Efficacy numbers grab headlines, but for patients who'll be injecting these drugs weekly for months or years, tolerability matters just as much. Here's what we know about cagrisema side effects compared to Zepbound's safety profile.

CagriSema Safety Profile

Data from the REDEFINE 1 and REDEFINE 4 trials paints a consistent picture:

Gastrointestinal side effects dominate. Nausea was the most commonly reported adverse event -- affecting roughly 55% of CagriSema participants in REDEFINE 1. Vomiting, diarrhea, and constipation followed. These GI effects are expected with any drug that activates GLP-1 receptors, because slowing gastric emptying and altering gut signaling is part of how the drug works.

The important context: these GI side effects were described as mild to moderate in severity and typically diminished over time as patients' bodies adjusted. Most events occurred during the dose-escalation phase, when the drug was being ramped up to the full treatment dose.

Serious adverse events occurred in 9.8% of CagriSema participants in REDEFINE 1, which is within the range seen with other GLP-1 receptor agonists.

The overall safety profile was described as "safe and well-tolerated" in the published literature -- standard language, but supported by the data. For background on the cardiovascular implications of GLP-1 drugs as a class, see our overview of GLP-1 cardiovascular outcomes research.

Tirzepatide/Zepbound Safety Profile

Zepbound's side effect profile looks broadly similar. GI events -- nausea, diarrhea, constipation, vomiting -- are the most common complaints, consistent with its GLP-1 activity. Data from the SURMOUNT and SURPASS programs showed these effects followed the same pattern: most common during dose escalation, generally mild to moderate, and decreasing over time.

Tirzepatide has the advantage of a longer post-market track record, having been on the market since 2022 (as Mounjaro for diabetes) and since mid-2024 (as Zepbound for obesity). That real-world safety data hasn't turned up any major surprises beyond what the clinical trials identified.

Comparing the Two

A few things worth keeping in mind when reading side-by-side safety data from REDEFINE 4:

The trial was open-label. Both patients and researchers knew which drug each person was receiving. This can influence how side effects are reported -- patients who know they're on a newer, less-tested drug may be more attuned to symptoms. It doesn't invalidate the data, but it's a standard caveat for open-label trial safety reporting.

Both drugs share the GLP-1 GI side effect profile. Since both CagriSema and Zepbound activate GLP-1 receptors, the core pattern of nausea, vomiting, diarrhea, and constipation is present with both drugs.

CagriSema has amylin-specific considerations. Because cagrilintide acts on amylin receptors in addition to the GLP-1 pathway, there's a theoretical possibility of amylin-related effects that wouldn't show up with tirzepatide. The clinical trial data hasn't revealed any unique amylin-driven safety signals, but CagriSema's post-market track record is obviously nonexistent right now.

Tolerability could matter at scale. Even small differences in side effect severity or duration can influence which drug patients stick with long-term. Adherence is everything with these medications -- weight regain after discontinuation is well-documented. If one drug is slightly easier to tolerate, that could translate into better real-world outcomes over months and years.

For a broader look at how GLP-1 drugs perform beyond weight loss -- including cardiovascular, renal, and metabolic effects -- our clinical evidence review for obesity peptides covers the full evidence base.

VI. CagriSema vs Zepbound vs Wegovy: Three-Way Context

You can't fully understand what the REDEFINE 4 results mean without placing them alongside Wegovy (semaglutide 2.4 mg), the drug that started the modern obesity treatment revolution.

CagriSema vs Wegovy

This is where CagriSema looks strong. In REDEFINE 1, CagriSema produced 20.4% weight loss at 68 weeks. Semaglutide alone (the Wegovy arm of a related trial) produced about 14.9% over the same period. That's a roughly 5-6 percentage point advantage for CagriSema.

The REIMAGINE study told a similar story: CagriSema outperformed Ozempic (semaglutide at the diabetes dose) for weight loss in people with type 2 diabetes.

What does this tell us? The cagrilintide component genuinely adds weight loss on top of semaglutide. Pairing an amylin analog with a GLP-1 agonist produces more appetite suppression and more weight reduction than GLP-1 alone. The cagrisema vs wegovy comparison is clearly favorable for CagriSema.

Zepbound vs Wegovy

Zepbound also beats Wegovy. In every comparison -- whether head-to-head or cross-trial -- tirzepatide outperforms semaglutide for weight loss by a consistent margin. The SURMOUNT program showed up to 22.5% weight loss in the pivotal trials; the STEP program showed about 15% for semaglutide.

The Emerging Pecking Order

Based on the available data, the efficacy ranking for these three drugs looks like this:

Zepbound (tirzepatide) > CagriSema (semaglutide + cagrilintide) > Wegovy (semaglutide alone)

That hierarchy is based purely on average weight loss in clinical trials. Individual responses vary -- some patients respond better to one mechanism than another. And efficacy is only one factor. Safety profile, tolerability, availability, cost, and insurance coverage all influence which drug makes sense for a given patient.

For a broader look at how all the branded GLP-1 drugs stack up, see our branded GLP-1 drugs comparison.

VII. The Broader Next-Gen Obesity Drug Pipeline

CagriSema and Zepbound aren't the end of the story. Both Novo Nordisk and Eli Lilly have multiple next-generation compounds in development, and other pharma companies are racing to enter the market. Here's a snapshot of what's coming.

Novo Nordisk's Pipeline Beyond CagriSema

Novo isn't betting everything on CagriSema. The company has several programs running in parallel:

Cagrilintide monotherapy entered Phase 3 in 2025, testing whether the amylin analog alone can produce meaningful weight loss without a GLP-1 companion.

Zenagamtide (amycretin) is a single molecule that activates both GLP-1 and amylin receptors -- essentially doing in one compound what CagriSema does with two. Phase 3 trials were expected to begin in H1 2026. Early data was promising enough that analysts considered it Novo's most exciting pipeline asset.

UBT251 is a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. It's in Phase 1b/2 -- still early, but the triple-agonist concept has generated significant interest across the industry.

Higher-dose CagriSema trials are expected to begin dosing in H2 2026. If the current 2.4/2.4 mg dose produces 23% weight loss, could a higher dose narrow the gap with tirzepatide? That's the question this trial aims to answer.

Lilly's Pipeline Beyond Zepbound

Eli Lilly isn't standing still either:

Orforglipron is an oral GLP-1 agonist -- a pill instead of an injection. Phase 3 results in March 2026 disappointed the market, with weight loss numbers below expectations. But the convenience of oral dosing could still make it attractive for patients who refuse injections. See our full orforglipron oral GLP-1 profile.

Retatrutide is a triple agonist (GLP-1/GIP/glucagon) that produced jaw-dropping Phase 2 results -- up to 24% weight loss at 48 weeks, with the trajectory still going down. Phase 3 trials are ongoing. If retatrutide's Phase 3 data holds up, it could surpass both Zepbound and CagriSema. For the full Phase 2 breakdown, see our retatrutide Phase 2 trial analysis and our tirzepatide vs retatrutide comparison.

Other Companies Entering the Race

The obesity drug field isn't a two-company affair anymore:

Roche's CT-388 posted positive Phase 2 results in January 2026, showing the Swiss pharma giant is serious about entering the weight loss market.
Pfizer acquired Metsera for roughly $10 billion, signaling a massive commitment to obesity therapeutics after previous setbacks.
Amgen's MariTide is in development as a long-acting GIP receptor antagonist and GLP-1 agonist with a potentially less frequent dosing schedule.
Viking Therapeutics' VK2735 showed promising Phase 2 data and could offer another dual-agonist option.

For a comprehensive look at what's in development, see our overview of what's coming after current GLP-1 drugs.

The bottom line: the obesity drug market is nowhere near settled. The drugs that look like winners today could be second-tier options within two to three years. The pace of innovation is that fast.

VIII. FDA Timeline and Path to Market

So when can patients actually get CagriSema? And does losing the REDEFINE 4 head-to-head change the regulatory picture?

CagriSema's FDA Application

Novo Nordisk submitted CagriSema for FDA approval in December 2025, based on the REDEFINE 1 and REDEFINE 2 trial data. An FDA decision is anticipated in late 2026.

Here's what matters for the regulatory timeline: the REDEFINE 4 head-to-head results probably won't block approval. The FDA application was filed before the REDEFINE 4 data was available. The agency evaluates drugs based on their efficacy and safety compared to placebo -- not based on head-to-head comparisons with other approved drugs. And CagriSema's 20.4% weight loss vs placebo in REDEFINE 1 is still a very strong result.

Does Losing a Head-to-Head Matter for FDA Approval?

This question has come up constantly since the REDEFINE 4 results dropped. The short answer: probably not for approval, but it could affect labeling and competitive positioning.

The FDA doesn't require a new drug to beat existing treatments to get approved. It needs to demonstrate safety and efficacy compared to placebo (or standard of care, depending on the disease area). Twenty-three percent body weight loss is clinically significant by any standard.

Where the head-to-head data could matter is in the drug's labeling, post-marketing communications, and -- critically -- in how physicians and insurance companies evaluate it relative to Zepbound, which is already on the market.

The Broader Regulatory Picture

The obesity drug regulatory environment is shifting fast:

Oral semaglutide (a higher-dose version of Rybelsus) received FDA approval for weight management in December 2025, giving patients an injection-free option with the same active ingredient as Wegovy.
Orforglipron (Lilly's oral GLP-1) is awaiting its own FDA timeline after the March 2026 Phase 3 readout.
Supply chain issues continue to affect the GLP-1 market. Drug shortages have been a persistent problem, and adding new drugs to the approved roster could help alleviate demand. For the latest on availability, see our coverage of GLP-1 drug shortages and alternatives.

IX. What This Means for Patients

Numbers and trial acronyms are useful, but what patients really want to know is: how does this affect my treatment options? Let's walk through some specific scenarios.

If You're Currently on Wegovy or Ozempic

CagriSema would represent an upgrade from your current medication. The REDEFINE 1 and REDEFINE 2 data consistently show that adding cagrilintide to semaglutide produces roughly 5-6 percentage points more weight loss than semaglutide alone. Same injection schedule (weekly). Same GLP-1 component you're already taking.

If CagriSema receives FDA approval in late 2026, it could be a logical next step for patients who've plateaued on semaglutide or who want additional weight reduction. Talk to your doctor about whether it makes sense to wait. For practical guidance, see our article on transitioning between GLP-1 medications.

If You're Considering Zepbound

The REDEFINE 4 data is clear: Zepbound demonstrated stronger average weight loss in the head-to-head trial (25.5% vs 23.0% on-treatment). If maximizing weight loss is the primary goal and you have access to Zepbound, the clinical data favors tirzepatide.

But "average" is the operative word. Both drugs achieved greater than 20% body weight loss, and individual responses vary widely. Some patients may respond better to the GLP-1/amylin combination (CagriSema) than to the GLP-1/GIP combination (Zepbound). Clinical trials report averages; your body isn't an average.

Both drugs produce clinically meaningful results. The difference between 23% and 25.5% is statistically real but may not be clinically transformative for every patient.

Access, Cost, and Practical Considerations

Right now, the decision between CagriSema and Zepbound isn't really a decision -- because CagriSema isn't available yet. Zepbound is FDA-approved and on the market (supply chain permitting). CagriSema is awaiting FDA review with a decision expected in late 2026.

When CagriSema does reach the market, the practical factors that influence drug choice will include:

Insurance coverage: Which drugs your plan covers at what tier. This varies enormously.
Out-of-pocket cost: List prices, copay assistance programs, and manufacturer coupons.
Supply availability: GLP-1 drug shortages have been a recurring problem. See our GLP-1 drug shortages coverage.
Your physician's recommendation: Based on your specific health profile, comorbidities, and treatment history.

This is emphatically a conversation to have with your healthcare provider. No article -- this one included -- can substitute for medical advice tailored to your situation.

The "23% vs 25.5%" Question: Does It Matter Clinically?

Let's put these numbers in perspective.

Five years ago, a drug that produced 10% body weight loss was considered a major success. The 5% threshold -- long used as the minimum for "clinically meaningful weight loss" -- now looks quaint. Both CagriSema and Zepbound blow past it by a factor of four.

The 2.5 percentage point gap between CagriSema and Zepbound matters from a competitive standpoint. It matters for stock prices. It matters for marketing. But for an individual patient, the difference between losing 23% and 25.5% of their body weight may be less significant than the headlines suggest.

Consider: for a 250-pound person, that gap translates to about 6 pounds of difference. Over 84 weeks. Both outcomes represent life-changing weight reduction that can improve cardiovascular risk, metabolic health, mobility, and quality of life.

A 2026 systematic review and meta-analysis published in the American Journal of Cardiology confirmed that CagriSema produces significantly more weight loss than semaglutide alone across multiple randomized trials. The drug works. It just doesn't work quite as well as tirzepatide in this particular comparison.

X. Key Takeaways

Here are the five most important things to walk away with from the REDEFINE 4 trial and the CagriSema vs Zepbound comparison:

1. Zepbound won the head-to-head. Tirzepatide 15 mg produced 25.5% weight loss vs CagriSema's 23.0% over 84 weeks. CagriSema did not meet the primary endpoint of non-inferiority. That's an objective fact, and it matters.

2. CagriSema still works. Twenty-three percent weight loss is an extraordinary clinical result. It's better than semaglutide alone. It's better than any GLP-1 drug available five years ago. Losing the head-to-head doesn't erase that.

3. Two different approaches produced different outcomes. CagriSema targets GLP-1 + amylin. Zepbound targets GLP-1 + GIP. The dual-agonist approach (Zepbound) outperformed the dual-mechanism combination (CagriSema) in this trial. Whether that holds true across different patient populations and doses remains to be seen.

4. This isn't the final chapter. Novo Nordisk is testing higher doses of CagriSema, developing zenagamtide (a single-molecule GLP-1/amylin agonist), and pursuing triple agonists. Lilly has retatrutide in Phase 3. Other companies are entering the field. The drug that's "best" today may not hold that position for long.

5. Patients have options -- and will have more. Whether CagriSema, Zepbound, Wegovy, or something not yet approved turns out to be the right choice depends on individual factors that no clinical trial average can capture. The most productive thing you can do is bring this information to your doctor and have an informed conversation about your specific situation.

The obesity drug field is evolving faster than at any point in medical history. More head-to-head data is coming. More drugs are entering the pipeline. And for the millions of people living with obesity, that competition is nothing but good news.

For a broader look at what the science says about peptide-based treatments for weight management, explore our evidence-based fat loss peptide guide.

Last reviewed: March 2026. This article is for educational purposes only and does not constitute medical advice. Always discuss treatment options with a qualified healthcare provider.